Sandoz Estimates $200-$400 Generic Tirzepatide as Canada Warns on Fakes

Swiss manufacturer Sandoz has estimated its proposed generic tirzepatide product would cost between $200 and $400 per month without insurance, according to a Healthline report on the company's U.S. regulatory filings. The estimate lands as Health Canada continues to warn Canadian consumers about unauthorized and counterfeit GLP-1 products circulating in stores and online.

The U.S. filing and its Canadian context

The U.S. Food and Drug Administration has agreed to review two Sandoz applications for generic versions of tirzepatide medications marketed by Eli Lilly under the Mounjaro and Zepbound brands. The FDA typically completes reviews of standard drug applications within 10 months, according to information cited by Healthline.

Eli Lilly holds U.S. patent protection on both brand-name products until 2036, meaning generic tirzepatide cannot be sold in the United States before that date absent special permission. Lilly Canada maintains its official Mounjaro brand website at ca.lilly.com.

Sandoz statement

Claire D'Abreu-Hayling, president of Generics Development and chief scientific officer at Sandoz, said in a press statement cited by Healthline that the submission "represents a key first step in our efforts to bring this medicine to market and underscores our ambition to increase competition and expand affordability in a critical area of healthcare need".

Healthline reports that the brand-name products can cost more than $1,000 per month if not covered by insurance in the United States. Current Canadian pharmacy prices tracked on GLP1Prices.ca for Mounjaro range from $271.62 to $800 CAD, and for Zepbound from $276.66 to $612.81 CAD, so the Sandoz U.S. estimate of $200-$400 sits below the top end of Canadian brand pricing.

Health Canada counterfeit advisory

In an advisory last updated January 21, 2026, Health Canada told Canadians to beware of unauthorized and counterfeit versions of GLP-1 receptor agonist products. The regulator identified various retailers in Canada selling unauthorized GLP-1 products, both in stores and online, and noted that some websites and social media advertisements misuse official Health Canada logos and display fake endorsements to mislead consumers.

Health Canada emphasized that it never endorses a health product and does not allow its logo to be used in advertising or packaging. The advisory lists risks of unauthorized products including:

• containing too much, too little, or none of the active ingredient
• containing unlisted or unknown ingredients
• containing contaminants such as solvents, heavy metals, particles, or microbials
• being poorly or incorrectly labelled
• being improperly manufactured or stored

The regulator noted additional risks specific to injectable products, including infections due to lack of sterility, allergic reactions, and other serious negative outcomes from contamination or improper handling.

How to verify a Canadian product

Health Canada advises consumers to buy prescription products only from a licensed pharmacy, avoid unauthorized products, and check the eight-digit Drug Identification Number (DIN) on the label against Health Canada's Drug Product Database. The Department is working with the Canada Border Services Agency to stop unauthorized shipments from entering the country.

Canadians looking for authorized brand pricing can compare licensed pharmacy listings for Ozempic, Wegovy, and Rybelsus, or track pending generic filings on our generic semaglutide tracker. Coverage questions can be checked through our insurance coverage checker, and common questions are addressed in the FAQ.

What it means for Canadian buyers

Sandoz's U.S. filings do not affect Canadian availability of tirzepatide, which remains authorized under the Mounjaro brand in Canada. The Healthline report notes patents on the brand-name tirzepatide products are expiring in countries outside the United States on different timelines than the 2036 U.S. date. Until any generic tirzepatide is authorized in Canada, Health Canada's guidance is unchanged: purchase only from licensed Canadian pharmacies and verify DINs.

This article is for informational purposes only and does not constitute medical advice.

Sources

• Mounjaro, Zepbound: Generic GLP-1 Drugs May Soon Be ...
• Thinking about buying GLP-1 drugs like Ozempic or ...
• Mounjaro® (tirzepatide injection) | Official Canadian website